Gilead Phase 2 of Trodelvy KEYTRUDA Combo: Promising v. Non-Small Cell Lung Cancer

  Results Show Encouraging Activity of Trodelvy in Combination with KEYTRUDA in 1L Metastatic NSCLC Across all PD-L1 Subgroups and Histologies Studied –

– Results Support Further Investigation of Trodelvy in Combination with KEYTRUDA in 1L Metastatic NSCLC–

https://finance.yahoo.com/news/gilead-phase-2-evoke-02-070100756.html